Helix Biopharma (HBPCF) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.59 to $0.60
• Volume: N/A
• Average Volume: 418 shs
• Market Capitalization: $45.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HBPCF Stock Analysis - Frequently Asked Questions

How have HBPCF shares performed this year?

Helix Biopharma's stock was trading at $0.4549 at the beginning of 2025. Since then, HBPCF stock has increased by 31.9% and is now trading at $0.60.

How were Helix Biopharma's earnings last quarter?

Helix Biopharma Corp. (OTCMKTS:HBPCF) posted its quarterly earnings results on Monday, June, 16th. The company reported ($0.02) earnings per share (EPS) for the quarter.

How do I buy shares of Helix Biopharma?

Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 6/16/2025
• Today: 8/31/2025
• Next Earnings (Estimated): 9/02/2025
• Fiscal Year End: 7/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HBPCF
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: 905-841-2300
• Fax: 905-841-2244
• Employees: 9
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -747.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.42
• Quick Ratio: 0.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 76,380,000
• Free Float: 70,573,000
• Market Cap: $45.83 million
• Optionable: Not Optionable
• Beta: -0.04